Page 51 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine EZH2 inhibition in ARID1A-deficient TNBC

therapeutic target for human solid tumors. Proc Natl Acad is enriched in basal-like breast cancers and predicts poor
Sci U S A. 2012;109(17):6662-6667. outcome. Am J Pathol. 2010;176(6):2911-2920.
doi: 10.1073/pnas.1121623109 doi: 10.2353/ajpath.2010.091125
61. Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, 71. Lee KM, Lin CC, Servetto A, et al. Epigenetic repression
first-in-class phase I trial of the anti-CD47 antibody of sting by MYC promotes immune evasion and resistance
HU5F9-G4 in patients with advanced cancers. J Clin Oncol. to immune checkpoint inhibitors in triple-negative breast
2019;37(12):946-953. cancer. Cancer Immunol Res. 2022;10(7):829-843.
doi: 10.1200/jco.18.02018 doi: 10.1158/2326-6066.Cir-21-0826
62. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin 72. Lee JV, Housley F, Yau C, et al. Combinatorial
exposure dictates the immunogenicity of cancer cell death. immunotherapies overcome MYC-driven immune
Nat Med. 2007;13(1):54-61. evasion in triple negative breast cancer. Nat Commun.
2022;13(1):3671.
doi: 10.1038/nm1523
doi: 10.1038/s41467-022-31238-y
63. Song X, Zhou Z, Li H, et al. Pharmacologic suppression
of B7-H4 glycosylation restores antitumor immunity 73. Cancer Genome Atlas Network. Comprehensive
in immune-cold breast cancers. Cancer Discov. molecular portraits of human breast tumours. Nature.
2020;10(12):1872-1893. 2012;490(7418):61-70.
doi: 10.1158/2159-8290.Cd-20-0402 doi: 10.1038/nature11412
64. Zhang X, Chang A, Zou Y, et al. Aspirin attenuates cardiac 74. Torrejon DY, Abril-Rodriguez G, Champhekar AS, et al.
allograft rejection by inhibiting the maturation of dendritic Overcoming genetically based resistance mechanisms to
cells via the NF-κB signaling pathway. Front Pharmacol. PD-1 blockade. Cancer Discov. 2020;10(8):1140-1157.
2021;12:706748. doi: 10.1158/2159-8290.Cd-19-1409
doi: 10.3389/fphar.2021.706748 75. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic
65. Li JG, Du YM, Yan ZD, et al. CD80 and CD86 knockdown Β-catenin signalling prevents anti-tumour immunity.
in dendritic cells regulates Th1/Th2 cytokine production in Nature. 2015;523(7559):231-235.
asthmatic mice. Exp Ther Med. 2016;11(3):878-884. doi: 10.1038/nature14404
doi: 10.3892/etm.2016.2989 76. Vu SH, Vetrivel P, Kim J, Lee MS. Cancer resistance to
66. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu- immunotherapy: Molecular mechanisms and tackling
Iyer SV. Phosphatidylserine reduces immune response strategies. Int J Mol Sci. 2022;23(18):10906.
against human recombinant factor VIII in hemophilia a doi: 10.3390/ijms231810906
mice by regulation of dendritic cell function. Clin Immunol.
2011;138(2):135-145. 77. Liang X, Fu C, Cui W, et al. Β-catenin mediates tumor-
induced immunosuppression by inhibiting cross-priming of
doi: 10.1016/j.clim.2010.10.006 CD8+ T cells. J Leukoc Biol. 2014;95(1):179-190.
67. Wang L, Li Z, Ciric B, Safavi F, Zhang GX, Rostami A. doi: 10.1189/jlb.0613330
Selective depletion of CD11C CD11b dendritic cells
+
+
partially abrogates tolerogenic effects of intravenous mog in 78. Platanias LC. Mechanisms of type-I-and type-II-interferon-
murine EAE. Eur J Immunol. 2016;46(10):2454-2466. mediated signalling. Nat Rev Immunol. 2005;5(5):375-386.
doi: 10.1038/nri1604
doi: 10.1002/eji.201546274
68. Zhou Y, Leng X, Luo X, et al. Regulatory dendritic cells 79. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes
induced by K313 display anti-inflammatory properties and in tumor cells as a mechanism of resistance to anti-CTLA-4
ameliorate experimental autoimmune encephalitis in mice. therapy. Cell. 2016;167(2):397-404.e9.
Front Pharmacol. 2019;10:1579. doi: 10.1016/j.cell.2016.08.069
doi: 10.3389/fphar.2019.01579 80. Peng W, Chen JQ, Liu C, et al. Loss of pten promotes
69. Sim WJ, Malinarich F, Fairhurst AM, Connolly JE. Generation resistance to T cell-mediated immunotherapy. Cancer
of immature, mature and tolerogenic dendritic cells with Discov. 2016;6(2):202-216.
differing metabolic phenotypes. J Vis Exp. 2016;(112):54128. doi: 10.1158/2159-8290.Cd-15-0283
doi: 10.3791/54128 81. Papa A, Pandolfi PP. The PTEN-PI3K axis in cancer.
Biomolecules. 2019;9(4):153.
70. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D,
Olopade OI, Goss KH. Wnt/Beta-catenin pathway activation doi: 10.3390/biom9040153

Volume 3 Issue 1 (2025) 43 doi: 10.36922/arnm.5132